LEO Pharma's net-zero targets validated by SBTi
The company aims for net-zero by 2050 and near-term reductions by 2035, shifting from target-setting to implementation.
See the latest news and media coverage for LEO Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medical dermatology pharmaceutical company
leo-pharma.comLast updated
In short: LEO Pharma returned to profitability and achieved 10% revenue growth in 2025, while advancing a potential IPO and expanding its dermatology pipeline.
The company aims for net-zero by 2050 and near-term reductions by 2035, shifting from target-setting to implementation.
The first patient visit marks a milestone in the global study, part of ongoing innovation to address patient needs.
LOQTORZI is combined with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer. Clinical data show improved survival.
It achieves 9% CER growth, improved profitability, and acquired Replay, while advancing Anzupgo® and gaining Enstilar® approval in China.
Launches its own copy In collaboration with Prasco Laboratories, Leo Pharma launches its own copy version of the drug Dovonex to gain a share of the copy market, while...
LEO Pharma's phase 3 trial for delgocitinib cream addresses the unmet therapeutic need in lichen sclerosus, a chronic inflammatory dermatosis with significant quality-of-life impact.
Growth and underlying earnings show good signs, but past sins mean that equity is again being eroded this year...
LEO Pharma has announces that it will acquire Replay, a gene therapy company focused on developing transformative treatments for rare genetic dermatological conditions. LEO will...
Track LEO Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to LEO Pharma and other trending companies.